STOK compared with NGNE: revenue, margins and what each company keeps, and the suppliers and customers both name

STOKStoke Therapeutics, Inc.

Mkt capRevenueRevenue

NGNENeurogene Inc.

Mkt capRevenueRevenue

Compare

STOKStoke Therapeutics, Inc.

NGNENeurogene Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only STOK 3

BIIBBiogen International GmbHcustomer

ACADAcadia Pharmaceuticalscustomer

—NWALP PHOP Property Ownerunlistedsupplier

Shared 0

No disclosed counterparties: NGNE.

Only NGNE 0

None

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

STOKStoke Therapeutics, Inc.

26.46▲+0.64%· post 26.46

Mkt cap$1.7BRevenue$9MQ2 FY26Revenue$184MFY25

NGNENeurogene Inc.

26.72▼−3.01%· post 26.72

ClosedNov 2 '26

Mkt cap$621.3MRevenue$925,000Q2 FY24Revenue—

Compare

ClosedNov 2 '26

STOKStoke Therapeutics, Inc.

NGNENeurogene Inc.

26.46▲+0.64%post 26.46

Price

26.72▼−3.01%post 26.72

$1.7B

Mkt cap

$621.3M

Q2 FY26$9M

Revenue

$925,000Q2 FY24

FY25$184M

Revenue

—

STOK26.46▲+0.64%vsNGNE26.72▼−3.01%ClosedNov 2 '26